Back to Journals » OncoTargets and Therapy » Volume 9

MiR-29c inhibits cell growth, invasion, and migration of pancreatic cancer by targeting ITGB1

Authors Lu Y, Hu J, Sun W, Li S, Deng S, Li M

Received 20 July 2015

Accepted for publication 9 November 2015

Published 30 December 2015 Volume 2016:9 Pages 99—109

DOI https://doi.org/10.2147/OTT.S92758

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Xie Maohua

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Yebin Lu, Juanjuan Hu, Weijia Sun, Shengyu Li, Shuangya Deng, Ming Li

Department of General Surgery, Xiangya Hospital, Central South University, Changsha, People’s Republic of China

Abstract: MiR-29c is frequently dysregulated in many cancers; however, the roles of miR-29c in pancreatic cancer (PC) and underlying mechanisms remain poorly understood. In this study, we investigated the role of miR-29c in PC. Using quantitative real-time polymerase chain reaction, we demonstrated that miR-29c was frequently downregulated in clinical PC tissues and cell lines. Overexpression of miR-29c significantly inhibited the proliferation, migration, and invasion of PC cells in vitro, which demonstrated that miR-29c acts as a tumor suppressor in PC cells. Further analysis revealed that ITGB1 is one of the functional target genes of miR-29c, and knockdown of ITGB1 inhibited the proliferation, migration, and invasion of PC cells, which was similar to the effects of overexpression of miR-29c. Taken together, our results highlight the significance of miR-29c–ITGB1 interaction in the development and progression of PC.

Keywords: miR-29c, tumor suppressor, pancreatic cancer, ITGB1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]